陈建忠药学院药学药物化学，药物设计，先导化合物优化和构效关系个人简介:陈建忠，博士，浙江大学药学院教授，博导。1990年7月毕业于原杭州大学化学系（现浙江大学化学系），获理学学士学位，同年9月进入中国科学院上海药物研究所攻读研究生学位，分别于1993年和1996年获得有机化学理学硕士和理学博士学位，并留所担任助理研究员从事科研工作。作为主要研究人员之一于1997年获得中国科学院自然科学二等奖。1998年7月赴美国University of Connecticut药学院从事新药研发的基础性科研工作，并于2005年8月获得药学专业哲学博士学位。之后，继续分别在University of Houston药学院和University of Pittsburg药学院博士后研究。2008年9月回国任浙江大学药学院教授，博士生导师，主要开展药物设计和先导化合物发现的科学研究以及药物代谢分子机制的理论研究。获得包括国家自然科学基金，十一·五国家新药创制重大专项关键技术项目，浙江省钱江人才计划，浙江省自然科学基金重点项目等科研项目资助。在包括PNAS，J. Biol. Chem. J. Med. Chem. ACS Med. Chem. Lett. Eur. J. Med. Chem. J. Phys. Chem. Proteins，Int. J. Pharmaceu.，J. Chem. Info. Model. Curr. Med. Chem. Mol. BioSys. Mol. Diver.等学术期刊上发表60余篇学术论文，以及近10项国际专利和中国专利申请或授权。教学与课程:主讲：本科生课程：药物波谱解析本科生课程：药物设计参讲：研究生课程：药物设计研究生课程：蛋白质药学科研:1. 国家自然科学基金项目：新型大麻素CB2受体拮抗剂的药物设计、合成、和药理学评价（No. 30973637 2010.01~2012.12 项目负责人）2. 国家“十一.五”新药创制研究重大科技专项--新药研究开发关键技术：针对肿瘤、心脑血管等重大疾病的先导化合物结构优化设计的关键技术研究（2009.01~2010.12，总课题副组长，浙江大学课题负责人）3. 浙江省科技厅钱江人才计划：新型大麻素CB1受体拮抗剂的药物设计、合成、和药理学评价。项目编号：2010R100482010.8~2012.7，项目负责人。4. 国家自然科学基金项目：基于NMR和计算模拟的II相代谢酶UGT代谢机制研究，项目编号：81172983，2012.01~2015.12，项目负责人5. 浙江大学青年科研创新专项经费：新型大麻素CB2受体激动剂的药物设计、合成、和药理学评价，项目编号：5A7000-172210124，项目负责人6. 国家自然科学基金项目：DJ-1蛋白抑制剂的分子设计、构效关系、生物活性测试及生物学作用机制研究，项目编号：81473135 ，2015.01~2018.12，项目负责人.7. 新药研究国家重点实验室开放课题：基于复合物晶体结构的肿瘤因子DJ-1蛋白活性配体的药物设计、合成、和构效关系研究。项目编号：SIMM1501KF-02，课题负责人，2015.04~2016.05.8. 国家自然科学基金项目：针对多发性硬化症的CB2激动剂构效关系和生物学机制研究，项目编号：81773638，2018.1.1～2021.12.31，项目负责人。9.浙江省自然科学基金项目（重点）：CB2受体激动剂药代动力学性质优化的药物设计研究，项目编号：LZ18H300001，2018.1.1～2021.12.31，项目负责人。10.横向课题：化学物质QSAR估算，项目编号：K横20180214，2017.11.1～2022.10.31，项目负责人。研究与成果:近年来代表性轮文1.    H.-Y. Qian Z.-L. Wang Y.-L. Pan L.-L. Chen X. Xie* J.-Z. Chen*. Development of Quinazoline/Pyrimidine-24(1H3H)‑diones as Agonists of Cannabinoid Receptor Type 2. ACS Med. Chem. Lett. 2017 8 678–6812.    H.-Y. Qian Z.-L. Wang X.-Y. Xie Y.-L. Pan G.-J. Li X. Xie* J.-Z. Chen*. Developing pyridazine-3-carboxamides to be CB2 agonists: The design synthesis structure-activity relationships and docking studies. Eur. J. Med. Chem. 2017 137 598-611.3.    H.-Y. Qian S.-F. ChenY.-L. Pan J.-Z. Chen*. Understanding the relative affinity and specificity of the substrate binding site of protein kinase B for substrate-mimetic inhibitors. Mol. Simulat. 2017 17 1459-14714.    H. Qian J. Chen Y. Pan J.-Z Chen*. Molecular Modeling Studies of 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors through Receptor-Based 3D-QSAR and Molecular Dynamics Simulations，Molecules，2016 21 1222.5.    T. A. Chohan J.-J. Chen H.-Y. Qian，Y.-L. Pan，J.-Z. Chen*. Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations，Mol. BioSyst. 2016 12 1250~1268 6.    T. A. Chohan，H.-Y. Qian，Y.-L. Pan，J.-Z. Chen*. Molecular simulation studies on the binding selectivity of 2-anilino-4-(thiazol-5-yl)- pyrimidines in complexes with CDK2 and CDK7，Mol. Biosyst.，2016 12 145~161.7.    S. Han F.-F. Zhang H.-Y. Qian，L.-L. Chen，J.-B. Pu，X. Xie* J.-Z. Chen*. Development of quinoline-24(1H3H)-diones as potent and selectiveligands of the cannabinoid type 2 receptor，J. Med. Chem. 2015 58 5751~57698.     S. Han F.-F. Zhang H.-Y. L.-L. Chen X. Xie* J.-Z. Chen*. Design Syntheses Structure-Activity Relationships and Docking Studies of Coumarin Derivatives as Novel Selective Ligands for the CB2 Receptor. Eur. J. Med. Chem 2015 93 16-32.9.     T. A. Chohan H. Qian Y. Pan J.-Z. Chen*. Cyclin-dependent kinase-2 as a target for cancer therapy: Progress in the development of CDK2 inhibitors as anti-cancer agents. Curr. Med. Chem. 2015 22 237-26310.  Y. Cao S. Han L. Yu H. Qian J.-Z. Chen*. MD and QM/MM Studies on Long-Chain L‑α-Hydroxy Acid Oxidase:  Substrate Binding Features and Oxidation Mechanism. J. Phys. Chem. B 2014 118 5406-5417.11.  S. Han J.-J. Chen J.-Z. Chen*. Latest Progress in the Identification of Novel Synthetic Ligands for the Cannabinoid CB2 Receptor Mini-Rev. Med. Chem. 2014 14 426-443.12.  S. Han F.-F. Zhang X. Xie J.-Z. Chen* Design synthesis biological evaluation and comparative docking study of 124-triazolones as CB1 receptor selective antagonists. Eur. J. Med. Chem. 2014 74 73-8413.  Y. Cao Z.-J. Chen H.-D. Jiang and J.-Z. Chen*. Computational Studies of the Regioselectivities of COMT-Catalyzed Meta-/Para-O Methylations of Luteolin and Quercetin. J. Phys. Chem. B 2014 118 470-48114.  L. Yu J. Pu M. Zuo X. Zhang Y. Cao S. Chen Y. Lou Q. Zhou H. Hu H.Jiang J.-Z. Chen* S. Zeng*. Hepatic Glucuronidation of Isoneochamaejasmin A from the Traditional Chinese Medicine Stellera Chamaejasme L. Root. Drug Metab. Dispos. 2014 42 1–9.15.  S.-F. Chen Y. Cao S. Han J.-Z. Chen*.  Insight into the structural mechanism for PKB _ allosteric inhibition by molecular dynamics simulations and free energy calculations. J. Mol. Graph. Model. 48 (2014) 36–4616.  S.-F. Chen Y. Cao. J.-J. Chen J.-Z. Chen*.  Binding selectivity studies of PKBαusing molecular dynamics simulation and free energy calculations. J. Mol. Model. 2013 19:5097-511217.  S. Chen J.-Z. Chen* Development for anticancer therapy small-molecule inhibitors targeting protein kinase B. Mini-Rev. Med. Chem.2013 23:1272-129418.  J.-J. Chen Shuang Han Yang Cao Jian-Zhong Chen*The agonist binding mechanism of human CB2 receptor studied by molecular dnamics simulation free energy calculation and 3D-QSAR studies 药学学报2013，48:1436-1449，19.  L. Ou S. Han W. Ding Z. Chen Z. Ye H. Yang G. Zhang Y. Lou J.-Z. Chen* Y. Yu*. Design synthesis and 3D-QSAR study of cytotoxic flavonoid derivatives Mol. Diver. 2011 15:665–675.20.  L. Ou S. Han W. Ding P. Jia B. Yang J. L. Medina-Franco M. A. Giulianotti J.-Z. Chen* Y. Yu* Parallel synthesis of novel antitumor agents: 123-triazoles bearing biologically active sulfonamide moiety and their 3D-QSAR. Mol. Diver.  2011 15:927–946.21.  C. Jiang S. Han T. Chen J.-Z. Chen*. 3D-QSAR and docking studies of arylmethylamine-based DPP IV inhibitors Acta Pharmaceutica Sinica B 2012 2(4):411–42022.  J.-Z. Chen K.-Z. Myint X.-Q. Xie New QSAR prediction models derived from GPCR CB2-antagonistic triaryl bis-sulfone analogues by a combined molecular morphological and pharmacophoric approach. SAR and QSAR in Environmental Research. (2011) 22(5-6): 525–544.23.  刘瑶 洪岚 余露山 蒋惠娣 陈建忠 孟琴 陈枢青 曾苏，创新药物转化研究中ADME 的评价，药学学报，2011 46 (1): 19-2924.  J. Gertsch M. Leonti S. Raduner I. Racz J.-Z. Chen X.-Q. Xie K.-H. Altmann M. Karsak A. Zimmer Beta-caryophyllene is a dietary cannabinoid. PNAS 2008 105: 9099-901425.  X.-Q. Xie J.-Z. Chen Data-Mining Representative Small Molecule Drug Screening Database from NIH PubChem. J. Chem. Info. Model. 2008 48: 465-475.26.  S. Mao D. Probst S. Werner J.-Z. Chen X. Xie K. M. Brummond Diverging Rh(I)-Catalyzed Carbocylization Strategy to Prepare a Library of Unique Cyclic Ethers. J. Comb. Chem. 2008 10: 235-246.27.  J.-Z. Chen J. Wang X.-Q. Xie. GPCR Structure-Based Virtual Screening Approach for CB2 Antagonist Search. J. Chem. Info. Model. 2007 47(4) 1626-1637.28.  S. Raduner A. Majewska J.-Z. Chen X.-Q. Xie J. Hamon B. Faller K.-H. Altmann J. Gertsch. Alkylamides from Echinacea are a new class of cannabinomimetics. CB2-RECEPTOR DEPENDENT AND INDEPENDENT IMMUNOMODULATORY EFFECTS. J. Biol. Chem.，2006 281(20) 14192-14206.29.  J.-Z. Chen X.-W. Han Q. Liu A. Makriyannis J. Wang X.-Q. Xie. 3D QSAR Studies of Arylpyrazole Antagonists of CB1 and CB2 Cannabinoid Receptors. A Combined NMR and CoMFA Approach. J. Med. Chem.，2006 49 625-636.30.  J.-Z. Chen S. V. Ranade X.-Q. Xie. NMR characterization of paclitaxel/poly (styrene-isobutylene-styrene) formulations. Inter. J. Pharmaceut. 2005 305 129-14431.  Xiang-Qun Xie Jian-Zhong Chen. NMR structural comparison of the cytoplasmic juxtamembrane domains of G-protein coupled CB1 and CB2 receptors in membrane-mimetic DPC micelles. Journal of Biological Chemistry，2005 280(5) 3605-3612.32.  J.-Z. Chen X.-W. Han X.-Q. Xie. Preferred conformations of endogenous cannabinoid ligand anandamide. Life Sci. 2005 76: 2053-206933.  H. Qin B. J. Chakulski I. A. Rousseau J.-Z. Chen X.-Q. Xie P. T. G. S. Mather. Constable Bryan E. Coughlin.  Synthesis and characterization of unsaturated thermotropic polyesters prepared via acyclic diene metathesis polymerization. Macromolecules ，2004，37 5239-5249. 34.  X.-Q. Xie J.-Z. Chen E. M Billing. 3D structural model of the G-protein coupled cannabinoid CB2 receptor. Proteins，2003 53: 307- 319  